1.
|
9 p, 500.3 KB |
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
/
Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hillmen, Peter (St James Institute of Oncology) ;
O'Brien, S. (MD Anderson Cancer Center) ;
Barrientos, J.C. (Hofstra Northwell School of Medicine) ;
Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, S.E. (Stanford University) ;
Tam, Constantine S (Peter MacCallum Cancer Centre. St Vincent's Hospital) ;
Mulligan, S.P. (Royal North Shore Hospital) ;
Jaeger, U. (Medical University of Vienna) ;
Barr, P.M. (University of Rochester Cancer Center) ;
Furman, R.R. (New York Presbyterian Hospital) ;
Kipps, Thomas J (UCSD Moores Cancer Center) ;
Cymbalista, F. (Hôpital Avicenne) ;
Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ;
Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ;
Delgado, J. (Hospital Clínic i Provincial de Barcelona) ;
Montillo, M. (Niguarda Hospital) ;
DeVos, S. (David Geffen School of Medicine at UCLA) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Pagel, J.M. (Swedish Cancer Institute) ;
Munir, Talha (St James Institute of Oncology) ;
Burger, Jan A (MD Anderson Cancer Center) ;
Chung, D. (Pharmacyclics LLC. AbbVie Company) ;
Lin, J. (Pharmacyclics LLC. AbbVie Company) ;
Gau, L. (Pharmacyclics LLC. AbbVie Company) ;
Chang, B. (Pharmacyclics LLC. AbbVie Company) ;
Cole, G. (Pharmacyclics LLC. AbbVie Company) ;
Hsu, E. (Pharmacyclics LLC. AbbVie Company) ;
James, D.F. (Pharmacyclics LLC. AbbVie Company) ;
Byrd, J.C. (Ohio State University) ;
Universitat Autònoma de Barcelona
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. [...]
2018 - 10.1038/leu.2017.175
Leukemia, Vol. 32 Núm. 1 (january 2018) , p. 83-91
|
|
2.
|
19 p, 600.4 KB |
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
/
Barrientos, Jacqueline C. (Zucker School of Medicine at Hofstra/Northwell) ;
O'Brien, Susan (University of California Irvine) ;
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Kay, Neil E. (Mayo Clinic) ;
Reddy, Nishitha M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Tam, Constantine (Peter MacCallum Cancer Centre and St Vincent's Hospital) ;
Mulligan, Stephen (Royal North Shore Hospital) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Devereux, Stephen (King's College Hospital NHS Foundation Trust) ;
Pocock, Christopher (East Kent Hospitals University) ;
Robak, Tadeusz (Medical University of Lodz) ;
Schuster, Stephen J. (Perelman Center for Advanced Medicine) ;
Schuh, Anna (University of Oxford) ;
Gill, Devinder (Princess Alexandra Hospital) ;
Bloor, Adrian (The Christie Clinic) ;
Dearden, Claire (The Royal Marsden Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cull, Gavin (Sir Charles Gardiner Hospital) ;
Hamblin, Mike (Colchester Hospital) ;
Jones, Jeffrey A. (The Ohio State University Comprehensive Cancer Center) ;
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Suzuki, Samuel (Pharmacyclics LLC. an AbbVie Company) ;
Hsu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James University Hospital) ;
Universitat Autònoma de Barcelona
In the phase III study RESONATE, ibrutinib reduced the risk of progression and improved overall survival versus ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. [...]
2018 - 10.1016/j.clml.2018.08.007
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 12 (december 2018) , p. 803-813.e7
|
|
3.
|
14 p, 1.1 MB |
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
/
Kipps, Thomas J. (UC San Diego Moores Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute) ;
Barr, Paul M. (University of Rochester) ;
Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ;
O'Brien, Susan M. (University of California) ;
Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque) ;
Hillmen, Peter (University of Leeds) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Stilgenbauer, Stephan (University of Ulm) ;
Chanan-Khan, Asher A. (Mayo Clinic Cancer Center) ;
Mahler, Michelle (Janssen Research and Development) ;
Salman, Mariya (Janssen Research and Development) ;
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Balasubramanian, Sriram (Janssen Research and Development) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Londhe, Anil (Janssen Research and Development) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research and Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Hallek, Michael (University of Cologne) ;
Universitat Autònoma de Barcelona
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). [...]
2019 - 10.1016/j.clml.2019.07.004
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 11 (november 2019) , p. 715-722.e6
|
|
4.
|
13 p, 1.6 MB |
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
/
Arribas, Alberto J (SIB Swiss Institute of Bioinformatics) ;
Napoli, Sara (Università della Svizzera Italiana) ;
Cascione, Luciano (SIB Swiss Institute of Bioinformatics) ;
Sartori, Giulio (Università della Svizzera Italiana) ;
Barnabei, Laura (Università della Svizzera Italiana) ;
Gaudio, Eugenio (Università della Svizzera Italiana) ;
Tarantelli, Chiara (Università della Svizzera Italiana) ;
Mensah, Afua Adjeiwaa (Università della Svizzera Italiana) ;
Spriano, Filippo (Università della Svizzera Italiana) ;
Zucchetto, Antonella (Centro di Riferimento Oncologico di Aviano) ;
Rossi, Francesca M (Centro di Riferimento Oncologico di Aviano) ;
Rinaldi, Andrea (Università della Svizzera Italiana) ;
Castro de Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jovic, Sandra (Università della Svizzera italiana) ;
Bordone-Pittau, Roberta (Oncology Institute of Southern Switzerland) ;
Di Veroli, Alessandra (University of Perugia) ;
Stathis, Anastasios (Università della Svizzera Italiana) ;
Cruciani, Gabriele (University of Perugia) ;
Stussi, Georg (Oncology Institute of Southern Switzerland) ;
Gattei, Valter (Centro di Riferimento Oncologico di Aviano) ;
Brown, Jennifer R (Harvard Medical School) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zucca, Emanuele (Oncology Institute of Southern Switzerland) ;
Rossi, Davide (Oncology Institute of Southern Switzerland) ;
Bertoni, Francesco (Oncology Institute of Southern Switzerland) ;
Universitat Autònoma de Barcelona
PI3Kδ inhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell lymphoid tumors, including marginal zone lymphoma (MZL). [...]
2022 - 10.3324/haematol.2021.279957
Haematologica, Vol. 107 Núm. 11 (november 2022) , p. 2685-2697
|
|
5.
|
11 p, 1.8 MB |
Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
/
Munir, Talha (St. James's Hospital ( Dublín, Irlanda)) ;
Brown, J. R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
O'Brien, Susan (UC Irvine. Chao Family Comprehensive Cancer Center) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute (Estats Units d'Amèrica)) ;
Barr, Paul M (Wilmot Cancer Institute. University of Rochester Medical Center) ;
Reddy, N. M. (Vanderbilt-Ingram Cancer Center) ;
Coutre, Steven E. (Stanford Cancer Center. Stanford University School of Medicine) ;
Tam, C. S. (Peter MacCallum Cancer Centre. St. Vincent's Hospital and University of Melbourne) ;
Mulligan, S. P. (Royal North Shore Hospital) ;
Jaeger, Ulrich (Division of Hematology and Hemostaseology. Medical University of Vienna) ;
Kipps, T. J. (UCSD Moores Cancer Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Montillo, M. (Niguarda Ca' Granda Hospital) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Byrd, J. C. (The Ohio State University Comprehensive Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Dai, Sandra (Pharmacyclics LLC. an AbbVie Company) ;
Szoke, A. (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Woyach, J. A. (The Ohio State University Comprehensive Cancer Center) ;
Universitat Autònoma de Barcelona
Ibrutinib, a once-daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). [...]
2019 - 10.1002/ajh.25638
American Journal of Hematology, Vol. 94 Núm. 12 (january 2019) , p. 1353-1363
|
|